Business
Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform
Royalty Pharma plc (Nasdaq: RPRX) announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty business in Asia. Ken joins Royalty Pharma from Morgan Stanley, where he was Head of Asia Pacific Healthcare Investment Banking.
About this update from Royalty Pharma Plc
[{"type":"text","content":"NEW YORK, March 3, 2026 /PRNewswire/ -- Royalty Pharma plc (Nasdaq: RPRX) announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty business in Asia. Ken joins Royalty Pharma from Morgan Stanley, where he was Head of Asia Pacific Healthcare Investment Banking.","length":377,"tagName":"p"},{"type":"text","content":"Asia-based biotechnology companies are now prolific creators of innovative therapeutics. In 2025, the out-licensing of Chinese medicines alone comprised over $130 billion of announced transaction value, up from approximately $14 billion in 2021, as multinational pharmaceutical companies increasingly recognized the value of this innovation. This momentum is expected to continue into 2026 and beyond, as modalities, therapeutic areas and deal structures out of Asia become increasingly innovative, comprehensive and diverse.","length":525,"tagName":"p"},{"type":"text","content":"The royalties from these transactions are creating a new market opportunity for royalty-based funding. Royalty Pharma will partner with biotechnology innovators to build the royalty market in greater Asia, just as Royalty Pharma played a foundational role in establishing the biopharma royalty market in the west by working closely with universities, research institutions and biopharma companies over two decades ago.","length":418,"tagName":"p"},{"type":"text","content":""We are excited to welcome Ken, who has a deep and strategic understanding of the funding needs created by the incredible innovation occurring across Asia," said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. "On‑the‑ground expertise and strong local relationships are essential in Asia, where we see an important long‑term opportunity to fund innovation through royalties and other creative structures. Ken will be instrumental as we continue to expand our global platform."","length":534,"tagName":"p"},{"type":"text","content":""I am incredibly thrilled to join Royalty Pharma, the pioneer and undisputed leader of the royalty market," said Mr. Sun. "Royalty creation in Asia has grown rapidly and represents a potentially important new source of flexible, non-dilutive capital at significant scale to inn...